WHO | Antiretroviral therapy for HIV infection in adults and adolescents n.d. https://www.who.int/hiv/pub/arv/adult/en/ (accessed January 23, 2019).
 Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy 2006;26:1111–33. https://doi.org/10.1592/phco.26.8.1111.
 Sterling TR. When to start HAART: still a controversy. Report from Seattle: the 9th Conference on Retroviruses and Opportunistic Infections (CROI). Hopkins HIV Rep Bimon Newsl Healthc Provid 2002;14:1–3.
 Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008;197:1133–44. https://doi.org/10.1086/586713.
 When to start antiretroviral therapy: as soon as possible. - PubMed - NCBI n.d. https://www.ncbi.nlm.nih.gov/pubmed/?term=When+to+start+antiretroviral+therapy%3A+as+soon+as+possible. (accessed January 24, 2019).
 Kuznik A, Iliyasu G, Habib AG, Musa BM, Kambugu A, Lamorde M. Initiation of antiretroviral therapy based on the 2015 WHO guidelines. AIDS Lond Engl 2016;30:2865–73. https://doi.org/10.1097/QAD.0000000000001251.
 WHO | Antiretroviral therapy for HIV infection in adults and adolescents. WHO n.d. https://www.who.int/hiv/pub/arv/adult/en/ (accessed January 23, 2019).
 Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. https://doi.org/10.1056/NEJMoa1105243.
 WHO | Treat all people living with HIV, offer antiretrovirals as additional prevention choice for people at “substantial” risk n.d. https://www.who.int/mediacentre/news/releases/2015/hiv-treat-all-recommendation/en/ (accessed January 23, 2019).
 90–90–90 - An ambitious treatment target to help end the AIDS epidemic | UNAIDS n.d. http://www.unaids.org/en/90%E2%80%9390%E2%80%9390_publications (accessed January 23, 2019).
 Sidibé M, Loures L, Samb B. The UNAIDS 90-90-90 target: a clear choice for ending AIDS and for sustainable health and development. J Int AIDS Soc 2016;19:21133. https://doi.org/10.7448/IAS.19.1.21133.
 Brown AE, Hayes R, Noori T, Azad Y, Amato-Gauci AJ, Pharris A, et al. HIV in Europe and Central Asia: progress in 2018 towards meeting the UNAIDS 90-90-90 targets. Euro Surveill Bull Eur Sur Mal TransmEur Commun Dis Bull 2018;23. https://doi.org/10.2807/1560-7917.ES.2018.23.48.1800622.
 UNAIDS n.d. http://www.unaids.org/ (accessed January 23, 2019).
 Ndayishimiye E, Ross AJ. An audit of the screen-and-treat intervention to reduce cryptococcal meningitis in HIV-positive patients with low CD4 count. Afr J Prim Health Care Fam Med 2018;10:e1–7. https://doi.org/10.4102/phcfm.v10i1.1779.
 Weldegebreal T, Ahmed I, Muhiye A, Belete S, Bekele A, Kaba M. Magnitude of opportunistic diseases and their predictors among adult people living with HIV enrolled in care: national level cross sectional study, Ethiopia. BMC Public Health 2018;18:820. https://doi.org/10.1186/s12889-018-5733-x.
 Nansseu JRN, Bigna JJR. Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new “test and treat” policy of the World Health Organization? Infect Dis Poverty 2017;6:24. https://doi.org/10.1186/s40249-017-0240-3.
 Elharti E, Alami M, Khattabi H, Bennani A, Zidouh A, Benjouad A, et al. Some characteristics of the HIV epidemic in Morocco. East Mediterr Health J Rev Sante Mediterr Orient Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit 2002;8:819–25.
 A 30-year response to HIV in Morocco | UNAIDS n.d. https://www.unaids.org/en/resources/presscentre/featurestories/2018/january/20180119_morocco (accessed January 7, 2020).
 Pattanapanyasat K, Sukapirom K, Kowawisatsut L, Thepthai C. New BD FACSCount CD4 reagent system for simultaneous enumeration of percent and absolute CD4 T-lymphocytes in HIV-1-infected pediatric patients. Cytometry B Clin Cytom 2008;74 Suppl 1:S98-106. https://doi.org/10.1002/cyto.b.20415.
 Bergeron M, Ding T, Elharti E, Oumzil H, Soucy N, Harmouche H, et al. Evaluation of a dry format reagent alternative for CD4 T-cell enumeration for the FACSCount system: a report on a Moroccan-Canadian study. Cytometry B Clin Cytom 2010;78:188–93. https://doi.org/10.1002/cyto.b.20501.
 Bergeron M, Daneau G, Ding T, Sitoe NE, Westerman LE, Stokx J, et al. Performance of the PointCare NOW system for CD4 counting in HIV patients based on five independent evaluations. PloS One 2012;7:e41166. https://doi.org/10.1371/journal.pone.0041166.
 Pham MD, Agius PA, Romero L, McGlynn P, Anderson D, Crowe SM, et al. Performance of point-of-care CD4 testing technologies in resource-constrained settings: a systematic review and meta-analysis. BMC Infect Dis 2016;16:592. https://doi.org/10.1186/s12879-016-1931-2.
 Liang J, Duan S, Ma Y-L, Wang J-B, Su Y-Z, Zhang H, et al. Evaluation of PIMA point-of-care CD4 analyzer in Yunnan, China. Chin Med J (Engl) 2015;128:890–5. https://doi.org/10.4103/0366-6999.154283.
 Namuniina A, Lutwama F, Biribawa VM, Kizza D, Kabuubi BR, Kitandwe PK, et al. Field Performance of PIMA Point-of-Care Machine for CD4 Enumeration Under a Mobile HIV Counseling and Testing Program in Remote Fishing Communities of Lake Victoria, Uganda. AIDS Res Hum Retroviruses 2019;35:382–7. https://doi.org/10.1089/AID.2018.0223.
 Wade D, Daneau G, Aboud S, Vercauteren GH, Urassa WSK, Kestens L. WHO multicenter evaluation of FACSCount CD4 and Pima CD4 T-cell count systems: instrument performance and misclassification of HIV-infected patients. J AcquirImmune DeficSyndr 1999 2014;66:e98-107. https://doi.org/10.1097/QAI.0000000000000214.
 Thakar M, Mahajan B, Shaikh N, Bagwan S, Sane S, Kabra S, et al. Utility of the point of care CD4 analyzer, PIMA, to enumerate CD4 counts in the field settings in India. AIDS Res Ther 2012;9:26. https://doi.org/10.1186/1742-6405-9-26.
 Thakar M, Angira F, Pattanapanyasat K, Wu AHB, O’Gorman M, Zeng H, et al. CD4 Lymphocyte Enumeration and Hemoglobin Assessment Aid for Priority Decisions: A Multisite Evaluation of the BD FACSPrestoTM System. Open AIDS J 2017;11:76–90. https://doi.org/10.2174/1874613601711010076.
 Makadzange AT, Bogezi C, Boyd K, Gumbo A, Mukura D, Matubu A, et al. Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection. PloS One 2016;11:e0157546. https://doi.org/10.1371/journal.pone.0157546.
 Herbert S, Edwards S, Carrick G, Copas A, Sandford C, Amphlett M, et al. Evaluation of PIMA point-of-care CD4 testing in a large UK HIV service. Sex Transm Infect 2012;88:413–7. https://doi.org/10.1136/sextrans-2012-050507.
 Brief Clinical and Laboratory Monitoring of Pediatric HIV Infection Pediatric ARV. AIDSinfo n.d. https://aidsinfo.nih.gov/guidelines/brief-html/2/pediatric-arv/59/clinical-and-laboratory-monitoring-of-pediatric-hiv-infection (accessed January 28, 2019).
 De Santis GC, Brunetta DM, Vilar FC, Brandão RA, de AlbernazMuniz RZ, de Lima GMN, et al. Hematological abnormalities in HIV-infected patients. Int J Infect Dis IJID Off Publ Int Soc Infect Dis 2011;15:e808-811. https://doi.org/10.1016/j.ijid.2011.08.001.
 Daneau G, Aboud S, Prat I, Urassa W, Kestens L. Performance of FACSPresto Point-of-Care Instrument for CD4-T Cell Enumeration in Human Immunodeficiency Virus (HIV)-Infected Patients Attending Care and Treatment Clinics in Belgium and Tanzania. PloS One 2017;12:e0170248. https://doi.org/10.1371/journal.pone.0170248.